![The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Far1727/MediaObjects/13075_2004_Article_1606_Fig3_HTML.jpg)
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text
![Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology](https://www.jimmunol.org/content/jimmunol/174/11/7376/F1.large.jpg)
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
![HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-019-12163-z/MediaObjects/41467_2019_12163_Fig1_HTML.png)
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
![Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2a49fbd7-cfae-470e-8687-bde5d4faa11f/gr3.jpg)
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
![Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1567576921000345-gr3.jpg)
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
![NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology](https://journals.physiology.org/cms/10.1152/ajplung.00477.2005/asset/images/medium/zh50040644980001.jpeg)
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
![Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology](https://www.jimmunol.org/content/jimmunol/165/10/5962/F1.large.jpg)
Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology
![HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-019-12163-z/MediaObjects/41467_2019_12163_Fig5_HTML.png)
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
![NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology](https://journals.physiology.org/cms/10.1152/ajplung.00477.2005/asset/images/medium/zh50040644980002.jpeg)
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
![Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b3ea2865-3a31-4e94-9193-e53312b31bd8/gr1.gif)